Virax Biolabs Group (VRAX) Competitors $0.61 +0.02 (+3.38%) Closing price 08/28/2025 03:59 PM EasternExtended Trading$0.61 0.00 (-0.31%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. TXMD, IMCC, CTXR, PRPH, MRKR, BFRG, ALVR, LGVN, GELS, and SNGXShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include TherapeuticsMD (TXMD), IM Cannabis (IMCC), Citius Pharmaceuticals (CTXR), ProPhase Labs (PRPH), Marker Therapeutics (MRKR), Bullfrog AI (BFRG), AlloVir (ALVR), Longeveron (LGVN), Gelteq (GELS), and Soligenix (SNGX). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Its Competitors TherapeuticsMD IM Cannabis Citius Pharmaceuticals ProPhase Labs Marker Therapeutics Bullfrog AI AlloVir Longeveron Gelteq Soligenix Virax Biolabs Group (NASDAQ:VRAX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation. Which has higher valuation & earnings, VRAX or TXMD? TherapeuticsMD has higher revenue and earnings than Virax Biolabs Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$10K266.87-$6.06MN/AN/ATherapeuticsMD$1.76M7.36-$2.18MN/AN/A Do analysts rate VRAX or TXMD? Virax Biolabs Group presently has a consensus price target of $3.00, indicating a potential upside of 387.88%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts clearly believe Virax Biolabs Group is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is VRAX or TXMD more profitable? Virax Biolabs Group has a net margin of 0.00% compared to TherapeuticsMD's net margin of -17.94%. Virax Biolabs Group's return on equity of 0.00% beat TherapeuticsMD's return on equity.Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A TherapeuticsMD -17.94%-2.01%-1.40% Does the media prefer VRAX or TXMD? In the previous week, Virax Biolabs Group had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 4 mentions for Virax Biolabs Group and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.87 beat Virax Biolabs Group's score of -0.04 indicating that TherapeuticsMD is being referred to more favorably in the news media. Company Overall Sentiment Virax Biolabs Group Neutral TherapeuticsMD Very Positive Which has more volatility and risk, VRAX or TXMD? Virax Biolabs Group has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Do institutionals & insiders have more ownership in VRAX or TXMD? 8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 2.3% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryVirax Biolabs Group beats TherapeuticsMD on 10 of the 14 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.58M$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A21.0831.2726.59Price / Sales266.87350.07429.14155.79Price / CashN/A44.6737.7359.36Price / Book0.498.0910.196.68Net Income-$6.06M-$54.08M$3.27B$265.59M7 Day Performance-19.62%-0.41%1.37%0.66%1 Month Performance-33.66%6.23%6.17%2.64%1 Year Performance-87.85%10.45%43.98%22.36% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group2.9031 of 5 stars$0.61+3.4%$3.00+387.9%-87.4%$2.58M$10K0.005TXMDTherapeuticsMD0.6781 of 5 stars$1.16+1.7%N/A-42.3%$13.43M$2.56M0.00420IMCCIM Cannabis1.2109 of 5 stars$2.54-1.6%N/A-10.6%$13.34M$39.44M-4.70340Positive NewsGap UpCTXRCitius Pharmaceuticals2.9963 of 5 stars$1.23-10.9%$53.00+4,208.9%-90.3%$13.08MN/A0.0020PRPHProPhase Labs1.4349 of 5 stars$0.31-6.4%N/A-85.2%$12.98M$6.77M-0.25130Positive NewsMRKRMarker Therapeutics3.4589 of 5 stars$1.13-6.6%$13.17+1,065.2%-73.3%$12.79M$6.59M-0.8260Gap DownBFRGBullfrog AI0.8629 of 5 stars$1.26-4.5%N/A-47.9%$12.70MN/A-1.664Positive NewsALVRAlloVirN/A$2.50+1.6%N/A-82.4%$12.61MN/A-0.12110High Trading VolumeLGVNLongeveron3.7327 of 5 stars$0.83+2.3%$7.25+775.8%-60.9%$12.57M$2.39M-0.1320Positive NewsGELSGelteqN/A$1.28-0.8%N/AN/A$12.08M$100K0.00N/ASNGXSoligenix2.1737 of 5 stars$3.70-25.4%$6.00+62.2%-10.0%$12.06M$120K-0.9720 Related Companies and Tools Related Companies TherapeuticsMD Competitors IM Cannabis Competitors Citius Pharmaceuticals Competitors ProPhase Labs Competitors Marker Therapeutics Competitors Bullfrog AI Competitors AlloVir Competitors Longeveron Competitors Gelteq Competitors Soligenix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access